Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study.
- 1Department of Cardiology, King George's Medical University, Lucknow, 226003, Uttar Pradesh, India.
- 2Department of Pathology, King George's Medical University, Lucknow, 226003, Uttar Pradesh, India.
- 3Department of Cardiology, Indraprastha Apollo Hospital, New Delhi, 110076, India.
Abstract
Background
High-intensity statins are the cornerstone of post-ACS management. Real-world data frequently indicate suboptimal adherence and low attainment of guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets.Objective
This study aimed to evaluate the early efficacy of oral lipid-lowering therapy in achieving LDL-C targets following ACS in a recent cohort of Indian patients.Methods
This single-center prospective observational study enrolled 511 statin-naive ACS patients. High-intensity statin monotherapy (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) was initiated following diagnosis. Lipid profile, including total cholesterol, triglycerides, HDL-C, LDL-C, and VLDL-C, were assessed at baseline, Day 7, Day 14, and Day 28. Primary endpoints included the proportion of patients achieving LDL-C goals at Day 28.Results
50.5% of patients achieved the 2019 ESC/EAS LDL-C target (<55 mg/dL) at day 28. Similarly, 68.9% achieved the 2018 ACC/AHA target (<70 mg/dL), and 44.6% achieved the 2020 Lipid Association of India (LAI) target (<50 mg/dL) at day 28. The mean LDL-C reduced from 73.43 ± 13.99 mg/dL at Day 0 to 61.26 ± 27.00 mg/dL at Day 28, corresponding to a 16.6% reduction from baseline. On multivariate analysis, baseline LDL-C, type 2 diabetes mellitus and multivessel coronary disease were found to be independent negative predictors for achieving LDL-C goal <50 mg/dL at day 28.Conclusion
LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.
Related
- A prospective, observational study to evaluate the efficacy of the retrograde intrarenal surgery scoring system for predicting stone-free rate following retrograde intrarenal surgery.
- Ezetimibe Versus Alirocumab and Plaque Vulnerability in Patients with Acute Coronary Syndrome Not Achieving LDL-Cholesterol Target with Statin Therapy: The COMBI-LLT-ACS Randomized Trial.
- A Case of Advanced Hepatocellular Carcinoma with Macrovascular Invasion and Lung Metastases Achieving Pathological Complete Remission Following Sequential Multimodal Therapy: A Case Report.
- Evaluation of an Artificial Intelligence and Machine Learning Algorithm to Enhance Angiographic Coronary Visibility in Morbid Obesity: A Retrospective Observational Study
- Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention
BibTeX
@article{gautam2026early,
title = {{Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study.}},
author = {Ambresh Kumar Gautam and Sudesh Prajapathi and Abhishek Singh and Akshyaya Pradhan and Wahid Ali and Ayush Shukla and Monika Bhandari and Akhil Sharma and Pravesh Vishwakarma and Gaurav Chaudhary and Sharad Chandra and Rishi Sethi and Sudhanshu Dwivedi and Raman Puri},
journal = {American heart journal plus : cardiology research and practice},
year = {2026},
month = oct,
doi = {10.1016/j.ahjo.2026.100939},
url = {https://europepmc.org/article/MED/42898193},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Early efficacy of oral lipid lowering therapy in achieving LDL-C targets following acute coronary syndrome: A real-world observational study.
AU - Ambresh Kumar Gautam
AU - Sudesh Prajapathi
AU - Abhishek Singh
AU - Akshyaya Pradhan
AU - Wahid Ali
AU - Ayush Shukla
AU - Monika Bhandari
AU - Akhil Sharma
AU - Pravesh Vishwakarma
AU - Gaurav Chaudhary
AU - Sharad Chandra
AU - Rishi Sethi
AU - Sudhanshu Dwivedi
AU - Raman Puri
PY - 2026
DA - 2026/10/06
JO - American heart journal plus : cardiology research and practice
DO - 10.1016/j.ahjo.2026.100939
UR - https://europepmc.org/article/MED/42898193
AB - Background High-intensity statins are the cornerstone of post-ACS management. Real-world data frequently indicate suboptimal adherence and low attainment of guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets.Objective This study aimed to evaluate the early efficacy of oral lipid-lowering therapy in achieving LDL-C targets following ACS in a recent cohort of Indian patients.Methods This single-center prospective observational study enrolled 511 statin-naive ACS patients. High-intensity statin monotherapy (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) was initiated following diagnosis. Lipid profile, including total cholesterol, triglycerides, HDL-C, LDL-C, and VLDL-C, were assessed at baseline, Day 7, Day 14, and Day 28. Primary endpoints included the proportion of patients achieving LDL-C goals at Day 28.Results 50.5% of patients achieved the 2019 ESC/EAS LDL-C target (<55 mg/dL) at day 28. Similarly, 68.9% achieved the 2018 ACC/AHA target (<70 mg/dL), and 44.6% achieved the 2020 Lipid Association of India (LAI) target (<50 mg/dL) at day 28. The mean LDL-C reduced from 73.43 ± 13.99 mg/dL at Day 0 to 61.26 ± 27.00 mg/dL at Day 28, corresponding to a 16.6% reduction from baseline. On multivariate analysis, baseline LDL-C, type 2 diabetes mellitus and multivessel coronary disease were found to be independent negative predictors for achieving LDL-C goal <50 mg/dL at day 28.Conclusion LDL-C target attainment following ACS remains suboptimal despite high-intensity statin therapy, highlighting the need for earlier and more intensive lipid-lowering strategies in high-risk Indian patients.
SN - 2666-6022
ER -